Connor, Clark & Lunn Investment Management (CC&L)
PRTK

Connor, Clark & Lunn Investment Management (CC&L)’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-19,336
Closed -$61K – 1207
2020
Q1 		$61K Buy
+19,336
New +$71.3K ﹤0.01% 962

Other funds holding PRTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
GAI
General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s PRTK Position: Q2 2020 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q2 2020, closing a stake of 19,336 shares — an estimated $61K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in PRTK in Q1 2020 and held it in 1 quarter. The position peaked at $61K in Q1 2020. 99 funds tracked by Wall St. Rank hold PRTK as of Q2 2020.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Paratek Pharmaceuticals, Inc. position as of Q2 2020 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 19,336 Paratek Pharmaceuticals, Inc. shares in Q2 2020, an estimated $61K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Paratek Pharmaceuticals, Inc. in Q1 2020 and held it in 1 quarter.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Paratek Pharmaceuticals, Inc. position peaked at $61K in Q1 2020.
  • 99 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q2 2020.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2020, filed 13 Aug 2020.